In mice with experimental autoimmune myocarditis, IL1RAP blockade with mCAN10 preserved left ventricular ejection fraction compared to isotype controls (56.5% vs 51.0%, P=0.002).
Does IL1RAP blockade reduce myocarditis severity and preserve cardiac function in mice with viral or autoimmune myocarditis?
IL1RAP blockade reduces cardiac inflammation and preserves heart function in murine models of viral and autoimmune myocarditis, suggesting a potential novel therapeutic target.
Absolute Event Rate: 56.5% vs 51%
p-value: p=0.002
BACKGROUND: Currently, there are no therapies targeting specific pathogenic pathways in myocarditis. IL (interleukin)-1 blockade has shown promise in preclinical studies and case reports. We hypothesized that blockade of IL1RAP (IL-1 receptor accessory protein), a shared subunit of the IL-1, IL-33, and IL-36 receptors, could be more efficient than IL-1 blockade alone. METHODS: We induced coxsackievirus B3 (CVB3)–mediated or experimental autoimmune myocarditis (EAM) in BALB/c mice, followed by treatment with an Fc (fragment crystallizable)-modified mIgG2a mouse anti-mouse IL1RAP monoclonal antibody (mCAN10). Myocarditis severity and immune infiltration were assessed by histology and flow cytometry. Cardiac function was measured by echocardiography. We used spatial transcriptomics (Visium 10× Genomics) to compare the gene expression landscape in the hearts of mCAN10-treated versus control mice. RESULTS: IL1RAP blockade reduced CVB3 and EAM severity. In EAM, the treatment prevented deterioration of cardiac function, measured on day 42 post-disease induction (left ventricular ejection fraction: 56.5% versus 51.0% in isotype controls P =0.002 and versus 51.4% in mice treated with anti-IL-1β antibodies alone P =0.003; n=10–11 mice per group). In the CVB3 model, mCAN10 did not impede viral clearance from the heart and significantly lowered the numbers of CD4 + (cluster of differentiation 4) T cells ( P =0.025), inflammatory Ly6C + CCR2 + (lymphocyte antigen 6 complex, locus C/C-C motif chemokine receptor 2) monocytes ( P =0.038), neutrophils ( P =0.001) and eosinophils ( P <0.001) infiltrating the myocardium. The spatial transcriptomic analysis revealed reduced canonical IL-1 signaling and chemokine expression in cardiac immune foci in CVB3-infected mice treated with IL1RAP blockade. CONCLUSIONS: Blocking IL1RAP reduces acute CVB3 myocarditis and EAM severity and preserves cardiac function in EAM. We conclude that IL1RAP blockade is a potential therapeutic strategy in viral and autoimmune myocarditis.
Lema et al. (Fri,) conducted a other in Viral and autoimmune myocarditis. mCAN10 (anti-mouse IL1RAP monoclonal antibody) vs. Isotype controls and anti-IL-1β antibodies alone was evaluated on Left ventricular ejection fraction on day 42 post-disease induction (in EAM) (p=0.002). In mice with experimental autoimmune myocarditis, IL1RAP blockade with mCAN10 preserved left ventricular ejection fraction compared to isotype controls (56.5% vs 51.0%, P=0.002).